According to Topmidia News on April 28th, Brazilian Senator Soraya Thronicke spoke out against the decision made by Brazil's National Health Surveillance Agency (Anvisa) to maintain the ban on e-cigarettes. The Senator had previously met with major players in the global tobacco industry and advocated for regulation of such products.
Suraya emphasized that the ban will only benefit organized crime and goes against the principles of most developed countries.
Anvisa has brought the worst aspects of nicotine consumption to the people of Brazil.
The lawmaker expressed confusion over Anvisa's decision to maintain the ban on e-cigarettes. She tweeted, "We find this unanimous decision strange, at Anvisa, all resolutions are unanimous, this is too coincidental." She later posted another tweet stating, "Perhaps a public investigation can clarify these issues," sparking public skepticism about the fairness of Anvisa's decision-making. Currently, the lawmaker is being referred to as the "Tobacco Queen" by Brazilian media.
According to Anvisa, the injunction being maintained includes:
The ban on manufacturing, importing, selling, distributing, storing, transporting, and promoting all e-cigarette devices, including accessories, parts, and additives, will continue. Importing products into the country in any form, including personal luggage, remains prohibited. The approved regulations do not prohibit individual use.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
